company background image
1952 logo

Everest Medicines SEHK:1952 Stock Report

Last Price

HK$47.10

Market Cap

HK$15.3b

7D

-2.7%

1Y

118.6%

Updated

19 Apr, 2025

Data

Company Financials +

Everest Medicines Limited

SEHK:1952 Stock Report

Market Cap: HK$15.3b

1952 Stock Overview

A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details

1952 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

Everest Medicines Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Everest Medicines
Historical stock prices
Current Share PriceHK$47.10
52 Week HighHK$69.00
52 Week LowHK$18.18
Beta1.7
1 Month Change-26.35%
3 Month Change21.39%
1 Year Change118.56%
3 Year Change116.05%
5 Year Changen/a
Change since IPO-35.26%

Recent News & Updates

The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%

Apr 08
The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%
author-image

NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks

Mar 30 Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks.

Recent updates

The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%

Apr 08
The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%
author-image

NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks

Mar 30 Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks.

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Apr 27
Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 31
Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Jan 31
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Shareholder Returns

1952HK BiotechsHK Market
7D-2.7%1.2%1.9%
1Y118.6%57.8%19.2%

Return vs Industry: 1952 exceeded the Hong Kong Biotechs industry which returned 57.8% over the past year.

Return vs Market: 1952 exceeded the Hong Kong Market which returned 19.2% over the past year.

Price Volatility

Is 1952's price volatile compared to industry and market?
1952 volatility
1952 Average Weekly Movement13.2%
Biotechs Industry Average Movement13.5%
Market Average Movement7.9%
10% most volatile stocks in HK Market15.1%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 1952's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1952's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2017665Rogers Luowww.everestmedicines.com

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.

Everest Medicines Limited Fundamentals Summary

How do Everest Medicines's earnings and revenue compare to its market cap?
1952 fundamental statistics
Market capHK$15.28b
Earnings (TTM)-HK$1.11b
Revenue (TTM)HK$751.48m

20.3x

P/S Ratio

-13.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1952 income statement (TTM)
RevenueCN¥706.68m
Cost of RevenueCN¥177.79m
Gross ProfitCN¥528.89m
Other ExpensesCN¥1.57b
Earnings-CN¥1.04b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.21
Gross Margin74.84%
Net Profit Margin-147.36%
Debt/Equity Ratio12.9%

How did 1952 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/19 09:28
End of Day Share Price 2025/04/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Everest Medicines Limited is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited